MedTrace Logo

Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study

NCT05036031 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2021-09-05

No results posted yet for this study

Summary

The definition and diagnostic criteria of acute-on chronic liver failure (ACLF) differed evidently between the East and the West due to the difference in the underlying etiology. Liver transplantation is the most effective treatment to reverse the progress of ACLF and improve the survival rate of patients. The purpose of this study is to explore the accuracy of the two diagnostic criteria of EASL-CLIF and APASL ACLF in assessing the survival rate of patients with liver cirrhosis after LT.

Conditions

  • Acute-On-Chronic Liver Failure
  • Liver Cirrhosis
  • Liver Transplant; Complications

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Qiang Xia · Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU

  • Hao Feng · Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2021-10-01
Completion
2021-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05036031 on ClinicalTrials.gov